Pegasus Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Pegasus Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-24,675	Closed	-$1.9M	–	73
2022 Q1	$1.9M	Sell	24,675 -142	-0.6%	-$11.9K	0.83%	42
2021 Q4	$2.19M	Buy	24,817 +501	+2%	+$41.3K	0.9%	38
2021 Q3	$1.88M	Buy	24,316 +1,633	+7%	+$129K	0.86%	39
2021 Q2	$1.89M	Buy	22,683 +373	+2%	+$29.6K	0.88%	40
2021 Q1	$1.69M	Buy	22,310 +2,138	+11%	+$175K	0.86%	41
2020 Q4	$1.77M	Buy	20,172 +330	+2%	+$26.2K	0.97%	36
2020 Q3	$1.51M	Buy	19,842 +774	+4%	+$78.3K	0.95%	37
2020 Q2	$2.35M	Sell	19,068 -55	-0.3%	-$5.47K	1.61%	28
2020 Q1	$1.62M	Buy	19,123 +222	+1%	+$19.1K	1.33%	36
2019 Q4	$1.6M	Buy	+18,901	New	+$1.43M	1.05%	39

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Pegasus Asset Management's BMRN Position: Q2 2022 in Review

Pegasus Asset Management sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2022, closing a stake of 24,675 shares — an estimated $1.9M sold.

Pegasus Asset Management first reported a position in BMRN in Q4 2019 and held it in 10 quarters. The position peaked at $2.35M in Q2 2020. 542 funds tracked by Wall St. Rank hold BMRN as of Q2 2022.

Pegasus Asset Management reported no remaining BioMarin Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Pegasus Asset Management sold 24,675 BioMarin Pharmaceuticals shares in Q2 2022, an estimated $1.9M.
Pegasus Asset Management first reported a position in BioMarin Pharmaceuticals in Q4 2019 and held it in 10 quarters.
Pegasus Asset Management's BioMarin Pharmaceuticals position peaked at $2.35M in Q2 2020.
542 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2022.

Based on Pegasus Asset Management's 13F filing for Q2 2022, filed 1 Aug 2022.